CIPLA
Back to Balance Sheet
|
CIPLA Last 5 Year Contingent Liabilities History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Contingent Liabilities | ₹936 Cr | ₹634 Cr | ₹567 Cr | ₹743 Cr | ₹622 Cr |
What is the latest Contingent Liabilities ratio of CIPLA ?
| Year | Contingent Liabilities |
|---|---|
| Mar2025 | ₹936 Cr |
| Mar2024 | ₹634 Cr |
| Mar2023 | ₹567 Cr |
| Mar2022 | ₹743 Cr |
| Mar2021 | ₹622 Cr |
How is Contingent Liabilities of CIPLA Trending?
| Years | Contingent Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | ₹936 Cr | 47.65 | |
| Mar2024 | ₹634 Cr | 11.90 | |
| Mar2023 | ₹567 Cr | -23.73 | |
| Mar2022 | ₹743 Cr | 19.41 | |
| Mar2021 | ₹622 Cr | - | |
Compare Contingent Liabilities of peers of CIPLA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| CIPLA | ₹106,771.0 Cr | -1.9% | -0.3% | -6% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹431,628.0 Cr | 3.5% | 5.6% | 11.9% | Stock Analytics | |
| DIVIS LABORATORIES | ₹167,975.0 Cr | -1.3% | 4.5% | 16.2% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹145,804.0 Cr | -0.7% | 6.9% | 47.8% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹108,829.0 Cr | 1.3% | 5.1% | 17.5% | Stock Analytics | |
| MANKIND PHARMA | ₹90,257.8 Cr | -2.7% | 4.6% | -2.8% | Stock Analytics | |
CIPLA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| CIPLA | -1.9% |
-0.3% |
-6% |
| SENSEX | -4.1% |
-5.8% |
5.8% |
You may also like the below Video Courses